Table 4.

Association between industry payments and non-recommended or low value drugs. Associations are shown in terms of prevalence difference, paid minus not paid

Cohort	No of patients	No of oncologists	Unadjusted prevalence difference (%)	Estimated prevalence difference, % (95% CI)
				Patient characteristics model*	Physician indicator model
CSPC	9799	5367	18.0	17.5 (15.3 to 19.7)	7.4 (2.5 to 12.2)
GCSF	271 485	18 148	5.5	5.8 (5.4 to 6.1)	0.4 (−0.3 to 1.1)
Nab-paclitaxel	86 394	14 197	7.8	7.6 (7.1 to 8.1)	1.7 (0.9 to 2.5)
Branded drugs	13 386	7409	−4.8	−4.6 (−5.8 to −3.3)	1.2 (−6.0 to 8.5)

CI=confidence interval; CSPC=castration sensitive prostate cancer; GCSF=granulocyte colony stimulating factors.

^*Accounts for calendar year and patients’ characteristics.